Literature DB >> 21104073

Restless legs syndrome due to aripiprazole.

Juan Bolaños-Vergaray, Juan Carlos Obaya, Rafael Gonzalez, Cristina Echeverri, Pilar Piquer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21104073     DOI： 10.1007/s00228-010-0952-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  8 in total

Review 1.  Restless legs syndrome: a review of clinical and pathophysiologic features.

Authors:  R P Allen; C J Earley
Journal:  J Clin Neurophysiol       Date:  2001-03       Impact factor: 2.177

2.  Mirtazapine may have the propensity for developing a restless legs syndrome? A case report.

Authors:  Won-Myong Bahk; Chi-Un Pae; Jeong-Ho Chae; Tae-Youn Jun; Kwang-Soo Kim
Journal:  Psychiatry Clin Neurosci       Date:  2002-04       Impact factor: 5.188

3.  Impact, diagnosis and treatment of restless legs syndrome (RLS) in a primary care population: the REST (RLS epidemiology, symptoms, and treatment) primary care study.

Authors:  Wayne Hening; Arthur S Walters; Richard P Allen; Jacques Montplaisir; Andrew Myers; Luigi Ferini-Strambi
Journal:  Sleep Med       Date:  2004-05       Impact factor: 3.492

Review 4.  Restless legs syndrome: a clinical update.

Authors:  Charlene E Gamaldo; Christopher J Earley
Journal:  Chest       Date:  2006-11       Impact factor: 9.410

5.  Restless legs syndrome and periodic limb movements during sleep probably associated with olanzapine.

Authors:  Seung-Gul Kang; Heon-Jeong Lee; Leen Kim
Journal:  J Psychopharmacol       Date:  2008-06-18       Impact factor: 4.153

6.  Restless legs syndrome.

Authors:  Max Bayard; Thomas Avonda; James Wadzinski
Journal:  Am Fam Physician       Date:  2008-07-15       Impact factor: 3.292

7.  Refractory restless legs syndrome likely caused by olanzapine.

Authors:  Imran Khalid; Lopa Rana; Tabindeh J Khalid; Timothy Roehrs
Journal:  J Clin Sleep Med       Date:  2009-02-15       Impact factor: 4.062

8.  Restless legs syndrome symptoms in primary care: a prevalence study.

Authors:  Deborah A Nichols; Richard P Allen; John H Grauke; John B Brown; Matthew L Rice; Pamela R Hyde; William C Dement; Clete A Kushida
Journal:  Arch Intern Med       Date:  2003-10-27
  8 in total
  2 in total

Review 1.  Use of α2δ Ligands for Restless Legs Syndrome/Willis Ekbom Disease.

Authors:  Michele A Faulkner
Journal:  CNS Drugs       Date:  2018-02       Impact factor: 5.749

2.  Review of the treatment of restless legs syndrome: focus on gabapentin enacarbil.

Authors:  Rachel A Burke; Michele A Faulkner
Journal:  J Cent Nerv Syst Dis       Date:  2012-09-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.